



## **Tissue Regeneration Therapeutics Inc. Cell-Based Bioweapon Defense Technology Presented at the 2014 International Society for Stem Cell Research Conference.**

**Toronto, Canada, June 20<sup>th</sup> 2014:** Tissue Regeneration Therapeutics Inc. (TRT) today announced that pre-clinical research utilizing its patented mesenchymal stromal/stem cell (MSC) technology TXP, was presented at the International Society for Stem Cell Research conference in Vancouver June 19<sup>th</sup>.

Dr. Lorena R. Braid of the Defence Research and Development Canada, Suffield Research Centre, Bio-Threat Defence Section, presented significant pre-clinical data demonstrating that TXP cells transfected to release viral antibodies over a sustained period provided protection from lethal levels of virus exposure in an animal model, demonstrating its potential as a highly effective prophylactic biomedical countermeasure. The presented data is another important milestone in the advancement of the TRT platform technology into a broad range of defense and civilian therapeutic applications.

**TRT** is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP family of cell therapy products. TRT has discovered the world's richest source of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC platform technology are founded on the highly enriched source of these important cells compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal cells within the harvested population, their increased biological potential compared to cells derived from adult tissues and their inexhaustible supply.

### **About TRT**

TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP cell therapy products. TRT is the only company in the world to have issued and allowed patents in the USA, Europe and Australasia, for extraction of these unique cells from umbilical cord tissue. TRT provides license opportunities to collaborating partner companies in the regenerative medicine, defense, and family banking sectors. Additional information is available at <http://www.verypowerfulbiology.com>